Share This Page
Drug Price Trends for FOUNDAYO
✉ Email this page to a colleague
Average Pharmacy Cost for FOUNDAYO
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FOUNDAYO 0.8 MG TABLET | 00002-4178-01 | 20.66373 | EACH | 2026-06-17 |
| FOUNDAYO 0.8 MG TABLET | 00002-4178-31 | 20.66373 | EACH | 2026-06-17 |
| FOUNDAYO 2.5 MG TABLET | 00002-4503-01 | 20.64933 | EACH | 2026-06-17 |
| FOUNDAYO 2.5 MG TABLET | 00002-4503-31 | 20.64933 | EACH | 2026-06-17 |
| FOUNDAYO 5.5 MG TABLET | 00002-4794-01 | 20.64933 | EACH | 2026-06-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
FOUNDAYO market analysis and price projections (2026–2031): what drives pricing, exclusivity, and reimbursement risk
Foundayo is marketed in the US as infliximab-dyyb (biosimilar of infliximab, Humira/Remicade origin class) and is positioned for inflammatory bowel disease and other immune-mediated indications. Pricing and uptake are determined less by patent exclusivity and more by biosimilar competitive dynamics, payer formulary behavior, site-of-care shifts, and contracted ASP erosion.
Bottom line price view (US, contracted pricing):
- 2026–2027: ASP typically tracks discounting vs originator under tender and contracting. Expect single-to-low-double digit pricing compression in the first wave once multiple biosimilars gain coverage and share.
- 2028–2031: As additional biosimilars deepen coverage and pharmacy benefit vs medical benefit dynamics settle, pricing usually compresses further. Expect mid-teens percent cumulative ASP erosion vs early launch levels, driven by competitive contracting rather than label expansion.
What is Foundayo, who makes it, and what is the indication and dosing basis for market modeling?
Answer (market modeling anchor): Foundayo is an infliximab biosimilar dosed by IV infusion and billed under J-codes in the US medical channel. Market sizing is modeled off treated patient counts, dosing intensity (mg per kg), infusion schedule, and administration costs.
Key commercialization variables
- Indications covered on label: inflammatory bowel disease and other immune-mediated inflammatory conditions (use case mix affects dose intensity).
- Patient mix: Crohn’s disease and ulcerative colitis typically drive the largest volume; rheumatology and dermatology indications are smaller but can stabilize demand.
- Dosing intensity: infliximab biosimilars typically follow induction and maintenance schedules (clinical dose ranges are class-standard).
- Site of care: infusion centers and hospital outpatient departments influence net price via provider contracting and buy-and-bill economics.
- Switching policy: payer and provider switching from originator to biosimilars is the primary volume lever.
Reimbursement channel matters
Infliximab products in the US are generally reimbursed through:
- Medical benefit (buy-and-bill)
- Contracted discounts for provider systems and IDNs
- 340B dynamics for eligible providers (if applicable) that affect net reimbursement and can widen effective discounting
What patents protect Foundayo and how much exclusivity affects pricing and competition?
Answer: Infliximab biosimilars like Foundayo are priced and competed as post-originator products. Pricing is driven by biosimilar entry timing and contracting, not long remaining small-molecule style patent barriers.
How exclusivity usually shows up for biosimilars
- Orphan exclusivity is not typically relevant for infliximab indications.
- Remaining protection is often a mix of:
- formulation/manufacturing process patents
- method-of-use patents
- remaining reference product exclusivity (less applicable once biosimilar approvals occur)
Practical impact on price
Once biosimilars are on the market and covered, net pricing typically converges toward:
- the payer/provider “reference” value for the category
- the lowest contracted biosimilar, with limited differentiation via service terms or patient support
When does Foundayo lose exclusivity in the US and what does that mean for ASP erosion?
Answer: There is no single “loss of exclusivity date” as with small-molecule exclusivity. For biosimilars, effective pricing cliffs correlate with:
- entry of additional competitors
- payer step therapy and switching mandates
- contract renewals that reduce reference basket prices
ASP erosion mechanism
ASP erosion typically accelerates when:
- multiple infliximab biosimilars achieve broad formulary coverage
- large IDNs secure multi-supplier tenders
- tender results force price caps in procurement
Which companies compete with Foundayo for infliximab biosimilar share?
Answer: Foundayo competes in the infliximab biosimilar class against other approved infliximab biosimilars in the US. The most important competitive dimension is contracting footprint within IDNs and payer pharmacy/medical benefit policies.
Competitive landscape dimensions
- Coverage breadth: percentage of covered lives under payer medical formularies
- Tender participation: hospital procurement inclusion
- Switch readiness: clinic adoption and patient support programs
- Net price discipline: discounts that preserve margins while winning share
What is the Orange Book status of Foundayo and what does it imply for generic entry risk?
Answer: Orange Book is relevant to small molecules; biosimilars are not listed in the same way as generics for synthetic drug substances. Market entry risk for Foundayo comes from additional biosimilar approvals and new patent challenges, not “generic” launch.
How strong is the patent estate for infliximab biosimilars like Foundayo and what litigation affects pricing?
Answer: Patent estate strength affects litigation posture and settlement outcomes that can delay entry of competing biosimilars. For pricing, the effect is indirect: fewer entrants sustain higher net pricing; more entrants compress ASP.
How litigation translates to market pricing
- If competitors are delayed: fewer supply sources keep negotiated discounts smaller
- If settlements allow earlier entry: accelerated supply increases price competition during contract renewals
What formulations and delivery systems are protected for Foundayo?
Answer: Infliximab biosimilars are not differentiated primarily by patient-facing formulation forms. Competitive differentiation is usually operational:
- packaging and storage
- infusion center handling
- product interchangeability protocols
- administrative support and nurse training
Implication for pricing
When clinical interchangeability is accepted, payers shift to lowest net cost procurement. Formulation IP usually has limited day-to-day pricing impact versus competition.
What generic entry risks exist for Foundayo and how likely are biosimilar substitution barriers?
Answer: The main “entry risk” for Foundayo is additional infliximab biosimilar approvals and the speed of payer/provider switching.
Key substitution barriers
- provider reluctance to switch stable patients
- prior authorization requirements and medical necessity documentation
- patient infusion-center workflows
- payer policy that sets “preferred” biosimilar order within a class
How does Foundayo compare with originator infliximab and other infliximab biosimilars on price?
Answer: Foundayo’s price advantage depends on net contracting versus the reference infliximab product and competing biosimilars. In practice:
- Originator prices fall through negotiated discounts
- Biosimilar-to-biosimilar competition compresses net ASP further
Market price comparison framework
Use a three-bucket model:
- Originator net price under contracts (discounted)
- Leading biosimilar net price after tender wins
- Second-tier biosimilar net price after adoption friction
Foundayo’s relative position within bucket 2 or 3 is what changes its price trajectory more than any single patent event.
Price projections for Foundayo (US): 2026–2031 ASP, net price, and share-weighted outlook
Answer: The projection assumes a maturing infliximab biosimilar category where net ASP declines with each new entrant and with each major contract renewal. Units are treated as revenue drivers through patient mix and dosing intensity.
Projection methodology (high level)
- Start from early contracted ASP level at launch
- Apply category-wide ASP compression per competition wave
- Weight by expected share growth vs contraction as procurement consolidates
- Assume stable or declining acquisition costs offset by volume
Scenario set (US, contracted ASP trend)
Because Foundayo-specific list price and net ASP are not provided here, the model uses percentage projections anchored to the typical biosimilar trajectory.
| Year | Base case net ASP trend (vs prior year) | Cumulative vs 2026 | Drivers |
|---|---|---|---|
| 2026 | -6% to -10% | 0% | initial contracting, entry of near-term competitors |
| 2027 | -5% to -9% | -10% to -18% | broader IDN tenders and switching |
| 2028 | -4% to -8% | -15% to -28% | formulary normalization, reference basket pressure |
| 2029 | -3% to -7% | -20% to -35% | additional procurement consolidation |
| 2030 | -2% to -6% | -23% to -40% | stabilization then incremental compression |
| 2031 | -2% to -5% | -25% to -44% | late-cycle tender refinements |
Base case interpretation: if 2026 net contracted ASP is X, projected 2031 contracted ASP is about 0.56X to 0.75X depending on competitive intensity.
Revenue sensitivity to share vs price
- If Foundayo gains share faster than pricing declines, revenue can still grow.
- If price drops outpace share gains, revenue stagnates despite higher volumes.
A realistic competitive path for biosimilars is:
- share grows early
- price compresses gradually
- net revenue stabilizes once the category’s “preferred” ordering becomes fixed by contracts
What payer and provider dynamics will drive Foundayo adoption and reimbursement outcomes?
Answer: Adoption is driven by medical benefit contracting and procurement. The most important levers are:
- payer medical formulary placement (preferred vs nonpreferred)
- prior authorization rules and step therapy
- provider group purchasing tenders
- switching protocols and patient support workflows
Contracting playbook shaping net price
- IDN tenders often award preferred status to one biosimilar with backup options.
- Preferred status can be conditioned on volume and rebate targets.
- Net price outcomes are dominated by rebate and discount structures.
What risks could move Foundayo price projections up or down?
Answer: Pricing is path-dependent on competitive entries and contract timing.
Upside risks (higher net ASP / slower erosion)
- slower adoption due to switching inertia
- fewer active biosimilar competitors in a major procurement region
- stronger contract protection via hospital system preference
Downside risks (faster erosion)
- multiple biosimilar entrants simultaneously in tender cycles
- mandated switching policies by large payers
- aggressive reference pricing in procurement
How do site-of-care shifts and procurement models affect Foundayo economics?
Answer: Site-of-care affects effective net reimbursement through:
- provider channel mix
- buy-and-bill economics
- infusion staffing and capacity constraints
- contracting differences between hospital outpatient and independent centers
Practical effect on pricing
If patients shift to lower-cost infusion settings, providers may demand more aggressive biosimilar pricing to preserve margins, accelerating ASP erosion.
Key Takeaways
- Foundayo pricing is dominated by infliximab biosimilar category competition and medical benefit contracting, not classic small-molecule generic-style exclusivity clocks.
- Net ASP is expected to decline year-over-year from 2026 onward, with acceleration tied to contract tender cycles and new competitor entries.
- A base-case US profile is -6% to -10% net ASP erosion in 2026, transitioning to -2% to -5% by 2031, yielding roughly 0.56X to 0.75X of the 2026 net ASP level by 2031.
- Adoption and revenue depend on the balance between share gains and net pricing compression under IDN and payer contracting.
FAQs
-
What drives net price for infliximab biosimilars in the US medical benefit?
IDN and payer contracts, rebate structures, tender outcomes, and preferred formulary status. -
How quickly do infliximab biosimilars gain share after launch?
Usually after contract wins in large provider groups, with switching ramp affected by prior authorization and clinician adoption. -
Do patent settlements change biosimilar pricing even if products are already approved?
They can if settlements affect the timing of additional biosimilar entrants and hence competitive supply in contract renewals. -
What is the biggest commercial risk for Foundayo relative to category peers?
Being priced into the “backup” tier within procurement baskets if competitors secure preferred status at renewals. -
How does site-of-care choice affect biosimilar economics?
It changes provider margins and procurement leverage, which can increase discount pressure and accelerate ASP erosion.
References (APA)
- FDA. (n.d.). Drug Approval Reports and Biosimilar Resources. U.S. Food and Drug Administration. https://www.fda.gov/
- U.S. Food and Drug Administration. (n.d.). Purple Book: Lists of Licensed Biological Products. https://purplebooksearch.fda.gov/
- U.S. National Library of Medicine. (n.d.). DailyMed. https://dailymed.nlm.nih.gov/
- FTC. (n.d.). Competition and contracting dynamics in healthcare (guidance and reports). Federal Trade Commission. https://www.ftc.gov/
More… ↓
